Vitamin D and multiple sclerosis

Neurologist

Volumn 18, Issue 4, 2012, Pages 179-183

  Weinstock Guttman, Bianca ^a   Mehta, Bijal K ^b   Ramanathan, Murali ^c   Karmon, Yuval ^a   Henson, Lily Jung ^d   Halper, June ^e   Riskind, Peter ^f  

^a JACOBS NEUROLOGICAL INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SWEDISH MEDICAL CENTER   (United States)

^e The Consortium of Multiple Sclerosis Centers   (United States)

^f UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

disease progression; multiple sclerosis; vitamin D

Indexed keywords

BETA CAROTENE; CALCITRIOL; ERGOCALCIFEROL; ERGOSTEROL; VITAMIN D; VITAMIN D RECEPTOR;

BIOCHEMISTRY; CALCIUM ABSORPTION; CLINICAL STUDY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MEGADOSE; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; SKIN PIGMENTATION; VITAMIN D DEFICIENCY; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

ANIMALS; HUMANS; MULTIPLE SCLEROSIS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84863599861     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e31825bbf35     Document Type: Review

References (54)

1. Brahic M. Multiple sclerosis and viruses. Ann Neurol. 2010;68:6-8.
2. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: Decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses. 1986;21: 193-200. (Pubitemid 17201931)
3. Hutter CD, Laing P. Multiple sclerosis: Sunlight, diet, immunology and aetiology. Med Hypotheses. 1996;46:67-74. (Pubitemid 26075766)
4. Leibowitz U, Antonovsky A, Medalie JM, et al. Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation. J Neurol Neurosurg Psychiatry. 1966;29:60-68.
5. Marrie RA. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol. 2004;3:709-718. (Pubitemid 39535256)
6. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296: 2832-2838. (Pubitemid 44969183)
7. Acheson ED, Bachrach CA, Wright FM. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr Scand Suppl. 1960;35:132-147.
8. Carlyle IP. Multiple sclerosis: A geographical hypothesis. Med Hypotheses. 1997;49:477-486. (Pubitemid 28009182)
9. Hayes CE, Cantorna MT, DeLuca HF. Vitamin D and multiple sclerosis. Proc Soc Exp Biol Med. 1997;216:21-27.
10. Kragt J, van Amerongen B, Killestein J, et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler. 2009;15:9-15.
11. Kurtzke JF. Geography in multiple sclerosis. J Neurol. 1977;215: 1-26. (Pubitemid 8082347)
12. Milo R, Kahana E. Multiple sclerosis: Geoepidemiology, genetics and the environment. Autoimmun Rev. 2010;9:A387-A394.
13. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62:60-65. (Pubitemid 38082871)
14. McDowell TY, Amr S, Culpepper WJ, et al. Sun exposure, vitamin D and age at disease onset in relapsing multiple sclerosis. Neuroepidemiology. 2011;36:39-45.
15. Lucas RM, Ponsonby AL, Dear K, et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology. 2011;76:540-548.
16. Holick M. Vitamin D. Modern Nutrition in Health and Disease. 10th ed. Lippincott Williams & Wilkins: Philadelphia; 2006.
17. Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest. 2006;116:2062-2072. (Pubitemid 44162310)
18. Gelfand JM, Cree BA, McElroy J, et al. Vitamin D in African Americans with multiple sclerosis. Neurology. 2011;76: 1824-1830.
19. Smolders J. Vitamin D and multiple sclerosis: Correlation, causality, and controversy. Autoimmun Dis. 2011. doi:10.4061/ 2011/629538.
20. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26:662-687. (Pubitemid 41127276)
21. Smolders J, Damoiseaux J, Menheere P. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol. 2008;194:7-17.
22. Lemire JM, Archer DC. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest. 1991;87:1103-1107.
23. Chang SH, Chung Y, Dong C. Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. J Biol Chem. 2010;285:38751-38755.
24. Mahon BD, Gordon SA, Cruz J, et al. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol. 2003;134:128-132. (Pubitemid 36050838)
25. Smolders J, Thewissen M, Peelen E, et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One. 2009;4:e6635.
26. Simpson S Jr, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010;68:193-203.
27. Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol. 2010;67:618-624.
28. Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain. 2009;132(pt 5): 1146-1160.
29. Soilu-Hanninen M, Airas L, Mononen I, et al. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler. 2005;11:266-271. (Pubitemid 40775180)
30. van der Mei IA, Ponsonby AL, Dwyer T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol. 2007;254:581-590. (Pubitemid 46781963)
31. Smolders J, Menheere P, Kessels A, et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler. 2008;14:1220-1224.
32. Weinstock-Guttman B, Zivadinov R, Qu J, et al. Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2011;82:189-195.
33. Kimball SM, Ursell MR, O'Connor P, et al. Safety of vitamin D3 in adults with multiple sclerosis. Am. J. Clin. Nutr. 2007;86: 645-651. (Pubitemid 47435831)
34. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357: 266-281.
35. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004;89:5387-5391. (Pubitemid 39518413)
36. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 2008;93: 677-681. (Pubitemid 351398538)
37. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am. J. Clin. Nutr. 2006;84:694-697. (Pubitemid 44715649)
38. Trang HM, Cole DE, Rubin LA, et al. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin utr. 1998;68:854-858. (Pubitemid 28471068)
39. Wingerchuk DM, Lesaux J, Rice GP, et al. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76: 1294-1296. (Pubitemid 41208389)
40. Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010;74:1852-1859.
41. Garland CF, French CB, Baggerly LL, et al. Vitamin D supplement doses and serum 25-hydroxyvitamin D in the range associated with cancer prevention. Anticancer Res. 2011;31: 607-611.
42. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: Looking to the future. J Clin Oncol. 2005;23:3175-3185. (Pubitemid 46217457)
43. Linseisen J, Rohrmann S, Miller AB, et al. Fruit and vegetable consumption and lung cancer risk: Updated information from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2007;121:1103-1114. (Pubitemid 47101650)
44. Food and Nutrition Board at the Institute of Medicine. (2010). Consensus Report. Dietary reference intakes for calcium and vitamin D. Available at: Http://dietary-supplements.info.nih.gov/ factsheets/vitamind.asp/ 2010.
45. World Cancer Research Fund-American Insitute for Cancer Research. (2007). Nutrition, physical activity, and the prevention of cancer: A global perspective. Available at: Http://eprints.ucl.ac. uk/4841/1/4841.pdf.
46. Mannisto S, Smith-Warner SA, Spiegelman D, et al. Dietary carotenoids and risk of lung cancer in a pooled analysis of seven cohort studies. Cancer Epidemiol Biomarkers Prev. 2004;13: 40-48. (Pubitemid 38116619)
47. Albanes D, Heinonen OP, Huttunen JK, et al. Effects of alphatocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am. J. Clin. Nutr. 1995;62(suppl):1427S- 1430S.
48. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst. 1996;88:1550-1559. (Pubitemid 26374508)
49. Satia JA, Littman A, Slatore CG, et al. Long-term use of betacarotene, retinol, lycopene, and lutein supplements and lung cancer risk: Results from the VITamins And Lifestyle (VITAL) study. Am J Epidemiol. 2009;169:815-828.
50. Manson JE, Bassuk SS, Lee IM, et al. The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012;33:159-171.
51. Smolders J, Hupperts R, Barkhof F, et al. Efficacy of vitamin D(3) as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci. 2011;311:44-49.
52. Weinstock-Guttman B, Gallagher E, Baier M, et al. Risk of bone loss in men with multiple sclerosis. Mult Scler. 2004;10:170-175. (Pubitemid 38499910)
53. Bjelakovic G, Gluud LL, Nikolova D, et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev. 2011;7:CD007470.
54. Cannell JJ, Hollis BW, Zasloff M, et al. Diagnosis and treatment of vitamin D deficiency. Expert Opin Pharmacother. 2008;9: 107-118(Pubitemid 351233752)